A Study on Rheumatoid Arthritis Patients Treated With Rituximab

Rheumatoid Arthritis Clinical Trial

Official title:

Retrospective Data Collection on Rheumatoid Arthritis (RA) Patients Treated With Rituximab in Finland.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02622503
• Other study ID #: ML30146
• Status: Completed
• Phase: N/A
• First received: December 2, 2015
• Last updated: December 12, 2016
• Start date: April 2008
• Est. completion date: August 2008

Study information

• Verified date: December 2016
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to obtain an overall picture of rituximab treatments and treatment responses in RA patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Rheumatoid arthritis (RA) patients treated with rituximab in Finland

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Rituximab
This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Information on previous RA treatments		3 months	No
Primary	Information on rituximab treatment responses		3 months	No
Primary	Information on concomitant medications		3 months	No